Clinical Trials Logo

GI Bleeding clinical trials

View clinical trials related to GI Bleeding.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01584869 Completed - GI-bleeding Clinical Trials

Emergency Capsule Endoscopy in Severe GI-bleeding

Start date: December 2011
Phase: Phase 2/Phase 3
Study type: Interventional

Primary objective: Evaluation of capsule endoscopy in the emergency setting of severe GI-Bleeding.

NCT ID: NCT00950339 Completed - Clinical trials for Coronary Heart Disease

Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine

Start date: August 2009
Phase: Phase 4
Study type: Interventional

Current guidelines recommend the addition of proton pump inhibitors (PPI) to patients taking double anti-platelet therapy (Aspirin and Clopidogrel) to prevent upper GI bleeding1. Many post percutaneous coronary intervention (PCI) patients are treated with dual anti-platelet medications as well as PPI to prevent upper GI bleeding. Recently, it was shown that PPI interact with the P450 system in the liver and reduce the platelet inhibitory effect of Clopidogrel2,3. Clopidogrel is activated by CYP2C19, which also metabolizes PPI4. Furthermore, a recent article showed increased mortality in patients taking PPI and clopidogrel compared with patients taking clopidogrel without PPI protection5. The degree of reduction in the platelet inhibitory properties of clopidogrel might vary among the different PPI4. The use of PPI for GI protection in patients treated with dual anti-platelet therapy is not based on randomized trials, but rather on expert opinion. Since H2 blockers are also effective in preventing acid secretion and are not known to interact with the P450 system that affects clopidogrel, the investigators hypothesized that these group of drugs will not interfere with the positive antiplatelet effects of clopidogrel and therefore will offer a good alternative treatment option.